Bluebird Bio Aktie

June Occupancy Shows Continued Momentum in Execution of Clear, Compelling and Effective Strategy Set by Recently Refreshed, Fit-for-Purpose Board Election of Even a Single Ortelius Nominee Would Risk Compromising Brookdale's Strong Forward Momentum NASHVILLE, Tenn. , July 8, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") today reminds all Brookdale shareholders to vote the BLUE proxy card "FOR" ONLY Brookdale's eight superior and highly qualified director nominees in advance of the Company's upcoming 2025 Annual Meeting of Stockholders, scheduled to be held on July 11, 2025.» Mehr auf prnewswire.com

Brossard, Quebec--(Newsfile Corp. - June 9, 2025) - Further to its news release dated April 24, 2025, Mines D'Or Orbec Inc. (TSXV: BLUE) ("Orbec" or the "Company") is pleased to announce that it has completed the second and final tranche of its non-brokered private placement consisting of the sale of 8,600,000 units (the "Units") at a price of $0.05 per Unit, for aggregate gross proceeds of $430,000 (the "Offering"). Each Unit was comprised of one common share in the capital of the Company (a "Share") and one-half of one Share purchase warrant (each whole warrant, a "Warrant").» Mehr auf newsfilecorp.com

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebir.» Mehr auf businesswire.com